Inovioが商用皮内送達装置の追加開発支援で814万ドルを提供される

AsiaNet 79130 （1031）

【プリマスミーティング（米ペンシルベニア州）2019年6月10日PR Newswire＝共同通信JBN】Inovio Pharmaceuticals, Inc.（NASDAQ:INO）は10日、米国防脅威削減局（DTRA）の医療部門が、Inovioの新しい商用皮内送達装置のさらなる開発に資金を提供すると発表した。DTRAのMedical CBRN Defense Consortiumは、DTRA開発製品を含むInovioのワクチンおよび治療薬の投与に使用されるCELLECTRA（R）3PSPとしてブランド化された小型携帯型電池式皮内装置の開発でInovioを支援するため、814万ドルを提供する。新たな資金は、CELLECTRA 3PSPの開発に加え、この新しい装置を使用した米陸軍感染症医学研究所（USAMRIID）開発のDNAワクチンの研究にも充てられる。

Inovioの研究・開発担当副社長で同プログラムの主任研究員であるケイト・ブロデリック博士は「米政府がInovioのイノベーションの実績を高く評価し、当社の商用皮内ワクチン送達装置のさらなる開発を支援するためにこの資金を提供してくれていることを光栄に思う。当社のCELLECTRA 3PSPは小型で携帯型の使いやすい装置で、世界中に展開される態勢を整えている米軍部隊から、地元の薬局あるいはアフリカの田舎のような厳しい環境下でのワクチン投与まで、Inovioのワクチンおよび免疫療法へのより幅広いアクセスを可能にするだろう」と語った。

最近のInovioによる臨床試験では、InovioのHIV、エボラ、ジカワクチンの皮内送達は一貫して、高水準かつ強力なレベルの免疫反応をもたらした。PENNVAX（R）ワクチンの皮内送達を用いたHIVワクチン研究で、Inovioは参加者のほぼ100％が抗HIV抗体とCD4+ T細胞反応を示したことを実証した。

このプロジェクトは、Medical CBRN Defense Consortium（MCDC）と米政府との間の、Other Transaction Agreement（OTA）番号W15QKN-16-9-1002を通じて、米政府が資金を提供した。Inovioの装置開発に資金を提供しているMCDCは、商業ソースの最先端の研究・開発を活用するという米政府の関心に応えてつくられた。これはMCDCに、新しい革新的技術を使用した医学的対策を開発する機敏で柔軟な方法を提供している。具体的には、このプログラムは、軍事要員の任務の有効性向上に関連する、米国防総省の将来の医薬品や診断の要件をサポートしている。

▽Inovio Pharmaceuticals, Inc.について

Inovioは、がんと感染症を標的とした合成核技術の発見、開発、商品化に重点的に取り組む革新的バイオテクノロジー企業である。Inovioは独自の技術プラットフォームを抗原シークエンシングと送達に応用し、標的疾患に対する強力な免疫反応を活性化させている。この技術は生体内でのみ機能し、標的のがんや病原体に対する強力で完全に機能するT細胞と抗体反応を、絶え間なく活性化することが実証されている。Inovioの最先端臨床プログラムであるVGX-3100は、HPV関連子宮頸部前がんの治療薬として第3相試験に入っている。また、HPV関連がん、膀胱がん、膠芽細胞腫を標的とした免疫腫瘍プログラム開発が第2相試験中で、B型肝炎、ジカ、エボラ、MERS（中東呼吸器症候群）、HIV用のプラットフォーム開発プログラムもある。パートナーおよび共同研究者には、アストラゼネカ、Regeneron（リジェネロン）、Roche/Genentech（ロシュ/ジェネンテック）、ApolloBio Corporation、GeneOne Life Science、ビル&メリンダ・ゲイツ財団、Coalition for Epidemic Preparedness Innovations、米国防高等研究計画局（DARPA）、国立衛生研究所（NIH）、国立アレルギー・感染症研究所、国立がん研究所、HIV Vaccines Trial Network、ウォルター・リード陸軍研究所、ウィスター研究所、ペンシルバニア大学が含まれている。詳細については、www.inovio.com を参照。

▽問い合わせ先

投資家向け

Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com

メディア向け

Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com

ソース：Inovio Pharmaceuticals, Inc.

Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device

PR79130

PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire=KYODO JBN/ --

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm

of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further

development of Inovio's new commercial intradermal delivery device. DTRA's

Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in

developing a small, portable, battery-powered intradermal device branded as

CELLECTRA(R) 3PSP to be used in the administration of Inovio's vaccines and

therapies which include DTRA developed products. In addition to the development

of CELLECTRA 3PSP, the new award will fund the investigation of DNA vaccines

developed by the U.S. Army Medical Research Institute of Infectious Diseases

(USAMRIID) using the new device.

Dr. Kate Broderick, Inovio's Senior Vice President of R&D and the Principal

Investigator of the program, said, "We are honored that the U.S. Government

considered highly of Inovio's track record of innovation and is providing this

funding to support the further development of our commercial intradermal

vaccine delivery device. Our CELLECTRA 3PSP is a small, portable user-friendly

device which will allow broader access to Inovio's vaccines and

immunotherapies, whether the vaccine is administered to our troops ready to be

deployed around the world, at a local pharmacy or in challenging settings such

as rural Africa."

In recent Inovio sponsored clinical studies, intradermal delivery of Inovio's

HIV, Ebola, and Zika vaccines resulted in consistently high and robust levels

of immune responses. In an HIV vaccine study using intradermal delivery of

PENNVAX(R) vaccine, Inovio demonstrated nearly 100% of participants displayed

anti-HIV antibody and CD4+ T cell responses.

The project was sponsored by the U.S. Government through Other Transaction

Agreement (OTA) number W15QKN-16-9-1002 between the Medical CBRN Defense

Consortium (MCDC), and the Government.  The MCDC that is funding Inovio's

device development, was formed in response to the U.S. government's interest in

leveraging cutting edge R&D from commercial sources. This gives MCDC an agile

and flexible way to develop medical countermeasures using new and innovative

technology. Specifically, this program supports the U.S. Department of

Defense's future medical pharmaceutical and diagnostic requirements as related

to enhancing the mission effectiveness of military personnel.

About Inovio Pharmaceuticals, Inc.  

Inovio is an innovative biotechnology company focused on the discovery,

development, and commercialization of its synthetic nucleic technology targeted

against cancers and infectious diseases. Inovio's proprietary technology

platform applies antigen sequencing and delivery to activate potent immune

responses to targeted diseases. The technology functions exclusively in vivo,

and has been demonstrated to consistently activate robust and fully functional

T cell and antibody responses against targeted cancers and pathogens. Inovio's

most advanced clinical program, VGX-3100, is in Phase 3 for the treatment of

HPV-related cervical pre-cancer. Also in development are Phase 2

immuno-oncology programs targeting HPV-related cancers, bladder cancer, and

glioblastoma, as well as platform development programs in hepatitis B, Zika,

Ebola, MERS, and HIV. Partners and collaborators include AstraZeneca,

Regeneron, Roche/Genentech, ApolloBio Corporation, GeneOne Life Science, The

Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness

Innovations, Defense Advanced Research Projects Agency, National Institutes of

Health, National Institute of Allergy and Infectious Diseases, National Cancer

Institute, HIV Vaccines Trial Network, Walter Reed Army Institute of Research,

The Wistar Institute, and the University of Pennsylvania. For more information,

visit www.inovio.com.

This press release contains certain forward-looking statements relating to our

business, including our plans to develop DNA-based immunotherapies, our

expectations regarding our research and development programs, including the

planned initiation and conduct of clinical trials and the availability and

timing of data from those trials. Actual events or results may differ from the

expectations set forth herein as a result of a number of factors, including

uncertainties inherent in pre-clinical studies, clinical trials and product

development programs, the availability of funding to support continuing

research and studies in an effort to prove safety and efficacy of

electroporation technology as a delivery mechanism or develop viable DNA

immunotherapies, our ability to support our pipeline of SynCon(R) active

immunotherapy and vaccine products, the ability of our collaborators to attain

development and commercial milestones for products we license and product sales

that will enable us to receive future payments and royalties, the adequacy of

our capital resources, the availability or potential availability of

alternative therapies or treatments for the conditions targeted by us or our

collaborators, including alternatives that may be more efficacious or cost

effective than any therapy or treatment that we and our collaborators hope to

develop, issues involving product liability, issues involving patents and

whether they or licenses to them will provide us with meaningful protection

from others using the covered technologies, whether such proprietary rights are

enforceable or defensible or infringe or allegedly infringe on rights of others

or can withstand claims of invalidity and whether we can finance or devote

other significant resources that may be necessary to prosecute, protect or

defend them, the level of corporate expenditures, assessments of our technology

by potential corporate or other partners or collaborators, capital market

conditions, the impact of government healthcare proposals and other factors set

forth in our Annual Report on Form 10-K for the year ended December 31, 2018,

our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019  and

other filings we make from time to time with the Securities and Exchange

Commission. There can be no assurance that any product candidate in our

pipeline will be successfully developed, manufactured or commercialized, that

final results of clinical trials will be supportive of regulatory approvals

required to market products, or that any of the forward-looking information

provided herein will be proven accurate. Forward-looking statements speak only

as of the date of this release, and we undertake no obligation to update or

revise these statements, except as may be required by law.

CONTACTS:     

Investors:  Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com

Media:      Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com

SOURCE  Inovio Pharmaceuticals, Inc.